Device Trial Radar · NCT04870047
Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
171
Actual
Start
Sep 3, 2021
Primary completion
Dec 4, 2024
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Phenox GmbHNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess safety and efficacy of p64 MW HPC Flow Modulation Device under single antiplatelet therapy compared to p64 MW Flow Modulation Device under dual antiplatelet therapy.
Conditions
- Intracranial Aneurysm
Interventions
Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation DeviceDevice
Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of DWI lesionsTime frame: 48 hours (± 24 hours)
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
CHU Bordeaux
Bordeaux, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
CHU de Lyon
Lyon, France
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.